Shun Lu, MD
Shanghai Chest Hospital
Emerging Leaders
not ranked
Current Leaders
#1757 pts
All-Time Leaders
#1,32818 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2009. 15 trials as lead/chair. How it works →
Trials led — by scientific impact
An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors
Phase 2RecruitingGenfleet Therapeutics (Shanghai) Inc.
5
impact
An Open, Observational Clinical Study, 2-3 Cycles Treatment as Neoadjuvant Therapy for NSCLC With Stage IIB-IIIB
N/AUnknownShanghai Chest HospitalStudy Chair
3
impact
A Phase II, Open-label, Multicenter Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HS-10365 as First-Line Treatment for Patients With Locally Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Phase 2RecruitingJiangsu Hansoh Pharmaceutical Co., Ltd.
2
impact
Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification
Phase 3CompletedHutchison Medipharma Limited
2
impact
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study on Toripalimab Combined With Platinum-Based Doublet Drug Chemotherapy for Resectable, Stage II-III, Non-Small Cell Lung Cancer
Phase 3ActiveShanghai Junshi Bioscience Co., Ltd.
2
impact
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors
Phase 2CompletedInventisBio Co., Ltd
1
impact
The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China
N/AUnknownBerry Genomics Co., Ltd.Study Chair
1
impact
A Phase II Study to Assess the Safety and Efficacy of D-0316 in Patients With Locally Advanced/Metastatic Non Small Cell Lung Cancer Whose Tumors Are Epidermal Growth Factor Receptor Mutation Positive
Phase 2CompletedInventisBio Co., LtdStudy Chair
1
impact
A Multicenter, Randomized, Controlled, Double Blind, Double Simulated, Phase III Clinical Study of Befotertinib vs Icotinib for Postoperative Adjuvant Treatment of IB-IIIB (T3N2M0) Stage Non Small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Phase 3RecruitingBetta Pharmaceuticals Co., Ltd.Study Chair
1
impact
A Multi-center, Open-label, Phase IIIb Confirmatory Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Locally Advanced or Metastatic NSCLC Patients With MET Exon 14mutations
Phase 3CompletedHutchison Medipharma Limited
1
impact
A Phase II/III, Open-Label, Randomised Study to Assess the Safety and Efficacy of D-0316 Versus Icotinib as First Line Treatment in Patients With EGFR Sensitising Mutation, Locally Advanced or Metastatic NSCLC
Phase 3CompletedBetta Pharmaceuticals Co., Ltd.
1
impact
Efficacy and Safety of Aumolertinib with or Without Chemotherapy As First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing Epidermal Growth Factor Receptor Mutations: a Randomized, Controlled, Open-label, Phase 3 and Multicenter Clinical Study
Phase 3ActiveJiangsu Hansoh Pharmaceutical Co., Ltd.
0
impact
Mutation Profile Detection, Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy of Advanced NSCLC Patients in China
N/ACompletedGeneplus-Beijing Co. Ltd.
0
impact
An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetic of PLB1004 Capsules Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive NSCLC
Phase 2Not Yet RecruitingAvistone Pharmaceutical（Ningbo）Co., LTD.
0
impact
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profiles, and Preliminary Efficacy of SYS6023 in Patients With Advanced Solid Tumors
Phase 1RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Study Chair
0
impact
A Parallel, Open-label Phase II Clinical Study of Enarodustat (SAL-0951) Tablets in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
Phase 2RecruitingShenzhen Salubris Pharmaceuticals Co., Ltd.
0
impact
A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety
Phase 2ActiveMinghui Pharmaceutical (Hangzhou) Ltd
0
impact
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10386 in Participants With Advanced Solid Tumors
Phase 1RecruitingJiangsu Hansoh Pharmaceutical Co., Ltd.
0
impact
Prospective, Observational Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
N/AActiveShanghai Chest Hospital
0
impact
0
impact
A Phase Ib/II , Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Effects of SC0245 in Combination With Irinotecan in Patients With ES-SCLC
Phase 2UnknownBiocity Biopharmaceutics Co., Ltd.Study Chair
0
impact
A Phase I/II, Dose Escalation and Dose Expansion Study of MHB036C for Advanced Solid Tumor to Evaluate the Tolerability/Safety, Pharmacokinetics and Efficacy
Phase 2ActiveMinghui Pharmaceutical (Hangzhou) Ltd
0
impact
Phase I Study of Anti-EGFR/c-Met Bispecific Antibody MCLA-129 Combined With Befotertinib in Patients of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation To Evaluate The Safety, Pharmacokinetic Characteristics and Antitumor Activity
Phase 1Not Yet RecruitingBetta Pharmaceuticals Co., Ltd.Study Chair
0
impact
A Phase Ib Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC.
Phase 1UnknownJiangsu Hansoh Pharmaceutical Co., Ltd.
0
impact
An Open-label, Multi-center, Non-randomized Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).
Phase 2UnknownShanghai Miracogen Inc.
0
impact
An Open-label, Single-arm Phase II Study of Pembrolizumab Plus Lenvatinib in PD-L1 Positive Patients With TKI-resistant EGFR-mutated Advanced Non-small Cell Lung Cancer
Phase 2ActiveShanghai Chest Hospital
0
impact
An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.
Phase 1UnknownJiangsu Simcere Pharmaceutical Co., Ltd.
0
impact
A Phase II, Single Arm, Multicenter and Open Labelstudy Evaluating the Efficacy, Safety and Pharmacokinetics of HMPL-453 in Patient With Advanced Malignant Mesothelioma
Phase 2UnknownHutchison Medipharma Limited
0
impact
A Phase 1, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10241 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy
Phase 1UnknownJiangsu Hansoh Pharmaceutical Co., Ltd.
0
impact
A Prospective Study to Evaluate the Results of Different NGS- Panels in Mutation Detection and Tumor Mutation Burden(TMB) Calculation by Using Malignant Hydrothorax From NSCLC
N/AUnknownShanghai Chest Hospital
0
impact
High Dose Versus Routine Dose Icotinib in Pretreated Non-small Cell Lung Cancer Patients With Stable Disease: a Phase II Randomized Study
Phase 2UnknownBetta Pharmaceuticals Co., Ltd.
0
impact
Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study
Phase 2CompletedShandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
0
impact